Latest Actinium Pharmaceuticals Inc. (ATNM) Headlines
Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013
Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET.
Actinium to Host Advisory Meeting at the 2014 ASBMT and CIBMTR Conference
Marketwire - Wed Feb 26, 7:08AM CST
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host an advisory meeting with leading bone marrow transplant experts during the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in Grapevine, Texas on Saturday, March 1, 2014. The Company will present an agreement reached with the Food and Drug Administration (FDA) on the design of a single pivotal Phase III trial for approval of Iomab(TM)-B, Actinium's leading drug candidate. The advisory group will discuss the Iomab(TM)-B Phase III trial design, formation of a Scientific Advisory Board for Iomab(TM)-B and logistics of the Phase III trial.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Global Radiopharmaceuticals Market Insight Research Report
M2 - Tue Feb 11, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8p2r/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" report to their offering. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly. A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%. This segment is mainly dominated by isotopes like I-131, Sm-153, Re-186, Y-90, and Lu-177. It is expected that over the next 5-6 years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers. The increasing popularity and use of SPECT and PET scans, new and efficient technological equipment, increased awareness about radiopharmaceuticals among physicians and most importantly, the easy availability of radiopharmaceutical from cyclotrons are some of the major factors driving the global radiopharmaceutical market. Inspite of the market for radiopharmaceuticals growing rapidly, there are many challenges, like high cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals. Additionally, there are also some obstacles with regards to the manufacturing of radioisotopes, which need to be addressed to tap the opportunities. The global market for radiopharmaceuticals was estimated to be valued at approximately USD 5.3 billion in 2013. Owing to factors like the increasing adoption rates of PET and SPECT scanners, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons, coupled with significant developments in research and technology, this market is expected to record a CAGR of close to 15% to reach approximately USD 10.6 billion by 2018. Report Highlights: - Global Radio Pharmaceuticals Market Overview by Region - Target Patient Base by Region - Radiopharmaceuticals Market Regulation for US, Europe & Canada - Radioisotopes Used in Radiopharmaceuticals - Radiopharmaceutical Clinical Pipeline Insight - Profile of 87 Radiopharmaceuticals Drugs in Clinical Phase Companies Mentioned - AREVA Med - Actinium Pharmaceuticals - Avid Radiopharmaceuticals - Bayer HealthCare Pharmaceuticals - Cardinal Health - GE Healthcare - Immunomedics - Ion Beam Applications - Lantheus Medical Imaging - Lantheus Medical Imaging - Merck & Co - Navidea - Nordion - PETNET Solutions (Siemens Healthcare Global) For more information visit http://www.researchandmarkets.com/research/px8p2r/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Actinium Presenting at the 16th Annual BIO CEO & Investor Conference Today at 1:30 pm ET
Business Wire - Tue Feb 11, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 1:30 pm ET at the 16th Annual BIO CEO & Investor Conference. Dr. Kaushik J. Dave, President and CEO, will present a corporate update.
Actinium to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 16th Annual BIO CEO & Investor Conference from February 10th to 11th, 2014. Dr. Dave will present an overview of the company on Tuesday, February 11, 2014 at 1:30 pm ET.
MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave
Marketwire - Thu Jan 30, 7:30AM CST
MissionIR today announces the online availability of its interview with Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech and pharmaceutical experience. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.
Actinium Engages Goodwin Biotechnology to Supply Iomab(TM)-B for Its Phase 3 Clinical Study
Business Wire - Wed Jan 29, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc. ("Goodwin"). According to the agreement, Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab(TM)-B. Iomab(TM)-B will be used in preparing patients for hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT).
Actinium Pharmaceuticals Announces Engagement of MissionIR Investor Relations Services
Marketwire - Wed Jan 15, 7:30AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) (the "Company") today announces that they have engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
Actinium Pharmaceuticals Inc concludes USD6.6m private placement of common stock and warrants
M2 - Tue Jan 14, 6:41AM CST
Biopharmaceutical Company Actinium Pharmaceuticals Inc (ATNM.OB) reported on Monday the completion of the final tranche of USD3.311m to raise gross proceeds of USD6.64mm from the private placement of common stock and warrants.
Actinium Presenting at Biotech Showcase(TM) 2014 Today at 4:30 PM Pacific
Business Wire - Mon Jan 13, 12:25PM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 4:30 pm Pacific. Dr. Kaushik J. Dave, President and CEO, will present a corporate update at the Biotech Showcase(TM) 2014.
Actinium Closes on Approximately $6.6 Million in Private Placement
Business Wire - Mon Jan 13, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it has closed the final tranche of approximately $3,310,860 to bring total gross proceeds of approximately $6,636,720 million from the private placement of common stock and warrants to new and existing accredited investors (the "Offering"). The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,700 in order to cover over-allotments. The proceeds of the Offering will be used primarily for further development of Iomab(TM)-B, a Phase 3 clinical stage bone marrow conditioning agent for preparing patients for hematopoietic stem cell transplantation (HSCT) and Actimab-A, Actinium's lead drug candidate in multicenter Phase 1/2 trials in Acute Myeloid Leukemia (AML).
Actinium to Present at Biotech Showcase(TM) 2014
Business Wire - Tue Jan 07, 5:59AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the Biotech Showcase(TM) 2014 conference from January 13th to 15th, 2014. Dr. Dave will present a corporate update on Monday, January 13, 2014 at 4:30 pm Pacific.
Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
PR Newswire - Thu Jan 02, 6:00AM CST
MGT Capital Investments, Inc. (NYSE: MGT) is a holding company that just saw one of its subsidiary companies FANTD LLC set a new record for the highest single-day payout of half a million dollars to its online gamers. Use the following link to learn more about MGT: MGT Research Report
Actinium Announces Voting Results from Its Annual Shareholder Meeting
Business Wire - Mon Dec 30, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced the voting results from its annual general meeting of the Company's shareholders (the "meeting") which was held on Monday, December 23, 2013.
Actinium Completes Technology Transfer for Manufacturing of Its Lead Drug Candidate Iomab(TM)-B
Business Wire - Thu Dec 19, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomab(TM)-B (BC8-I-131), a drug being developed for therapeutic treatment of incurable blood cancers. The Company now intends to complete plans to scale-up, submit an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration and initiate a pivotal Phase 3 clinical trial in 2014.
Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
PR Newswire - Mon Dec 09, 3:05PM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 24th Annual Oppenheimer Healthcare Conference in New York from December 10th through 11th, 2013. Dr. Dave will present a corporate update on Wednesday, December 11, 2013 at 8:20 am Eastern.
Actinium Pharmaceuticals Announces Clinical Advisory Board Meeting At The 2013 ASH Conference
PR Newswire - Mon Dec 09, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the Company's clinical advisory board met during the American Society of Hematology's (ASH) 55th Annual Meeting and Exposition in New Orleans. The clinical advisory board discussed the results to date of the ongoing Phase 1/2 trial of Actimab-A for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. The clinical advisory board also discussed future developments of Actimab-A pending the final outcome of the Phase 1/2 trial.
Actinium Files Annual Report on Form 10-K for the Year Ended December 31, 2013
Business Wire - Wed Mar 05, 6:00AM CST
--Highlights Achievements for 2013
Actinium to Present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Wed Feb 26, 11:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announces that Kaushik J. Dave, Ph.D., President and CEO, will present at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club of New York, located at 1 West 54th Street, New York, NY, on Monday, March 3, 2014 at 9:05 AM ET.
Actinium to Host Advisory Meeting at the 2014 ASBMT and CIBMTR Conference
Marketwire - Wed Feb 26, 7:08AM CST
Actinium Pharmaceuticals, Inc. (OTCBB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host an advisory meeting with leading bone marrow transplant experts during the combined annual meetings of the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) in Grapevine, Texas on Saturday, March 1, 2014. The Company will present an agreement reached with the Food and Drug Administration (FDA) on the design of a single pivotal Phase III trial for approval of Iomab(TM)-B, Actinium's leading drug candidate. The advisory group will discuss the Iomab(TM)-B Phase III trial design, formation of a Scientific Advisory Board for Iomab(TM)-B and logistics of the Phase III trial.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Concise Analysis of the International Radiopharmaceuticals Market
M2 - Fri Feb 14, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ltj8g/radiopharmaceutica) has announced the addition of the "Concise Analysis of the International Radiopharmaceuticals Market" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: - Diagnostic Radiopharmaceuticals - Therapeutic Radiopharmaceuticals. The report profiles 69 companies including many key and niche players such as: - Actinium Pharmaceuticals Inc. - Advanced Medical Isotope Corporation - Alseres Pharmaceuticals Inc. - Bayer HealthCare Pharmaceuticals - Bracco Diagnostics Inc. - Cardinal Health Inc. - Covidien Plc - Eli Lilly and Company - Erigal Limited - EUSA Pharma (Europe) Ltd. - GE Healthcare - IBA Group - Immunomedics Inc. - Jubilant Life Sciences Limited - Lantheus Medical Imaging Inc. - Medi-Radiopharma Ltd. - Nordion Inc. - Peregrine Pharmaceuticals Inc. - PETNET Solutions Inc. - Positron Corporation - Singapore Radiopharmaceuticals Pte Ltd. - Triad Isotopes Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers & Trends 3. Market Challenges 4. Therapeutic Radiopharmaceutical Products Under Development 5. Imaging Agents - An Overview 6. Nuclear Medicine - An Overview 7. Product Overview 8. Product Innovations/Introductions 9. Product Innovations/Introductions In Recent Past- A Perspective Builder 10. Recent Industry Activity 11. Corporate Activity In The Recent Past - A Perspective Builder 12. Focus On Select Players 13. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79) - The United States (36) - Canada (2) - Japan (1) - Europe (28) - France (2) - Germany (2) - The United Kingdom (4) - Italy (2) - Spain (1) - Rest of Europe (17) - Asia-Pacific (Excluding Japan) (9) - Latin America (1) - Africa (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/5l...rmaceutica
Global Radiopharmaceuticals Market Insight Research Report
M2 - Tue Feb 11, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/px8p2r/global) has announced the addition of the "Global Radiopharmaceuticals Market Insight" report to their offering. Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly. A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market in the future. The other segment of the market is the therapeutic segment, which accounts for the remaining 10%. This segment is mainly dominated by isotopes like I-131, Sm-153, Re-186, Y-90, and Lu-177. It is expected that over the next 5-6 years horizon, this market would witness a steep increase owing to the introduction of many new products for treating lymphoma, colon cancer, lung cancer, prostate cancer, bone cancer and other persistent cancers. The increasing popularity and use of SPECT and PET scans, new and efficient technological equipment, increased awareness about radiopharmaceuticals among physicians and most importantly, the easy availability of radiopharmaceutical from cyclotrons are some of the major factors driving the global radiopharmaceutical market. Inspite of the market for radiopharmaceuticals growing rapidly, there are many challenges, like high cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals. Additionally, there are also some obstacles with regards to the manufacturing of radioisotopes, which need to be addressed to tap the opportunities. The global market for radiopharmaceuticals was estimated to be valued at approximately USD 5.3 billion in 2013. Owing to factors like the increasing adoption rates of PET and SPECT scanners, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons, coupled with significant developments in research and technology, this market is expected to record a CAGR of close to 15% to reach approximately USD 10.6 billion by 2018. Report Highlights: - Global Radio Pharmaceuticals Market Overview by Region - Target Patient Base by Region - Radiopharmaceuticals Market Regulation for US, Europe & Canada - Radioisotopes Used in Radiopharmaceuticals - Radiopharmaceutical Clinical Pipeline Insight - Profile of 87 Radiopharmaceuticals Drugs in Clinical Phase Companies Mentioned - AREVA Med - Actinium Pharmaceuticals - Avid Radiopharmaceuticals - Bayer HealthCare Pharmaceuticals - Cardinal Health - GE Healthcare - Immunomedics - Ion Beam Applications - Lantheus Medical Imaging - Lantheus Medical Imaging - Merck & Co - Navidea - Nordion - PETNET Solutions (Siemens Healthcare Global) For more information visit http://www.researchandmarkets.com/research/px8p2r/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Actinium Presenting at the 16th Annual BIO CEO & Investor Conference Today at 1:30 pm ET
Business Wire - Tue Feb 11, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 1:30 pm ET at the 16th Annual BIO CEO & Investor Conference. Dr. Kaushik J. Dave, President and CEO, will present a corporate update.
Actinium to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 16th Annual BIO CEO & Investor Conference from February 10th to 11th, 2014. Dr. Dave will present an overview of the company on Tuesday, February 11, 2014 at 1:30 pm ET.
MissionIR Exclusive Audio Interview With Actinium Pharmaceuticals CEO Dr. Kaushik J. Dave
Marketwire - Thu Jan 30, 7:30AM CST
MissionIR today announces the online availability of its interview with Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech and pharmaceutical experience. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.
Actinium Engages Goodwin Biotechnology to Supply Iomab(TM)-B for Its Phase 3 Clinical Study
Business Wire - Wed Jan 29, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc. ("Goodwin"). According to the agreement, Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab(TM)-B. Iomab(TM)-B will be used in preparing patients for hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT).
Actinium Pharmaceuticals Announces Engagement of MissionIR Investor Relations Services
Marketwire - Wed Jan 15, 7:30AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) (the "Company") today announces that they have engaged the investor relations services of MissionIR. Through a network of investor-oriented sites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital as well as improve shareholder value.
Actinium Pharmaceuticals Inc concludes USD6.6m private placement of common stock and warrants
M2 - Tue Jan 14, 6:41AM CST
Biopharmaceutical Company Actinium Pharmaceuticals Inc (ATNM.OB) reported on Monday the completion of the final tranche of USD3.311m to raise gross proceeds of USD6.64mm from the private placement of common stock and warrants.
Actinium Presenting at Biotech Showcase(TM) 2014 Today at 4:30 PM Pacific
Business Wire - Mon Jan 13, 12:25PM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting today at 4:30 pm Pacific. Dr. Kaushik J. Dave, President and CEO, will present a corporate update at the Biotech Showcase(TM) 2014.
Actinium Closes on Approximately $6.6 Million in Private Placement
Business Wire - Mon Jan 13, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that it has closed the final tranche of approximately $3,310,860 to bring total gross proceeds of approximately $6,636,720 million from the private placement of common stock and warrants to new and existing accredited investors (the "Offering"). The aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,700 in order to cover over-allotments. The proceeds of the Offering will be used primarily for further development of Iomab(TM)-B, a Phase 3 clinical stage bone marrow conditioning agent for preparing patients for hematopoietic stem cell transplantation (HSCT) and Actimab-A, Actinium's lead drug candidate in multicenter Phase 1/2 trials in Acute Myeloid Leukemia (AML).
Actinium to Present at Biotech Showcase(TM) 2014
Business Wire - Tue Jan 07, 5:59AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the Biotech Showcase(TM) 2014 conference from January 13th to 15th, 2014. Dr. Dave will present a corporate update on Monday, January 13, 2014 at 4:30 pm Pacific.
Pre-Market Update: MGT Capital Investments, National American University Holdings and Actinium Pharmaceuticals
PR Newswire - Thu Jan 02, 6:00AM CST
MGT Capital Investments, Inc. (NYSE: MGT) is a holding company that just saw one of its subsidiary companies FANTD LLC set a new record for the highest single-day payout of half a million dollars to its online gamers. Use the following link to learn more about MGT: MGT Research Report
Actinium Announces Voting Results from Its Annual Shareholder Meeting
Business Wire - Mon Dec 30, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced the voting results from its annual general meeting of the Company's shareholders (the "meeting") which was held on Monday, December 23, 2013.
Actinium Completes Technology Transfer for Manufacturing of Its Lead Drug Candidate Iomab(TM)-B
Business Wire - Thu Dec 19, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomab(TM)-B (BC8-I-131), a drug being developed for therapeutic treatment of incurable blood cancers. The Company now intends to complete plans to scale-up, submit an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration and initiate a pivotal Phase 3 clinical trial in 2014.
Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
PR Newswire - Mon Dec 09, 3:05PM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 24th Annual Oppenheimer Healthcare Conference in New York from December 10th through 11th, 2013. Dr. Dave will present a corporate update on Wednesday, December 11, 2013 at 8:20 am Eastern.
Actinium Pharmaceuticals Announces Clinical Advisory Board Meeting At The 2013 ASH Conference
PR Newswire - Mon Dec 09, 6:00AM CST
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that the Company's clinical advisory board met during the American Society of Hematology's (ASH) 55th Annual Meeting and Exposition in New Orleans. The clinical advisory board discussed the results to date of the ongoing Phase 1/2 trial of Actimab-A for newly diagnosed AML patients over the age of 60 in a single arm multicenter trial. The clinical advisory board also discussed future developments of Actimab-A pending the final outcome of the Phase 1/2 trial.
